Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anti-CD19 CAR-NK cells (Second Affiliated Hospital of Zhejiang University School of Medicine)
- Development stage
- Unknown
- Lead developer
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
Anti-CD19 CAR-NK cells is an investigational allogeneic cell therapy developed by the Second Affiliated Hospital, School of Medicine, Zhejiang University, for the treatment of refractory or relapsed systemic lupus erythematosus (SLE). The therapy consists of natural killer (NK) cells derived from healthy donors that are genetically engineered to express a chimeric antigen receptor (CAR) specific for CD19, a protein found on the surface of B cells. By targeting and depleting these B cells, the therapy aims to reset the immune system and reduce the production of autoantibodies characteristic of SLE. As an allogeneic "off-the-shelf" product, it potentially offers faster access and a more favorable safety profile, including lower risks of cytokine release syndrome (CRS) and neurotoxicity, compared to autologous CAR-T cell therapies.
- Other names
- CD19-targeted CAR-NK cellsCD-19-targeted CAR-NK cellsCD 19-targeted CAR-NK cellsallogeneic anti-CD19 CAR-NK cells
02
Targets
Beyond the preview
Go deeper on anti-CD19 CAR-NK cells (Second Affiliated Hospital of Zhejiang University School of Medicine).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anti-CD19 CAR-NK cells (Second Affiliated Hospital of Zhejiang University School of Medicine).